Comments (11)

Feb 9, 2018 - 11:41pm
gogetit, what's your opinion? Comment below:

ER and PE are extremely difficult. IB is possible if you network extensively are lucky in getting an interview. Exit opportunities are much more realistic and achievable when you are at the staff level.

Feb 10, 2018 - 9:45am
equitykick, what's your opinion? Comment below:

From what I've seen, ER and IB are both in the cards. Don't sit around waiting for them to find you though.

Feb 10, 2018 - 10:23am
BobTheBaker, what's your opinion? Comment below:

IB, ER, Esuric exited to Corp Dev from Big 4 valuation. I work in valuation for a non-big 4 (BDO/ Grant Thorton/ Weaver) and in my short time here ppl at my firm have left for IB and management consulting. To be fair that's non-MBB and lower level mid market firms.


  • 1
Best Response
Feb 10, 2018 - 9:07pm
Esuric, what's your opinion? Comment below:

This is a complicated question. I had an AMA that went into greater detail but unfortunately it was hijaked by trolls. That said, the exits vary somewhat dramatically by group. Big 4, with the possible exception of EY (haven't interacted with them) is broken down by industry vertical: TMT, Life Sciences, Financial Sponsors, Complex Securities (CLOs, RMBS, etc.), Aerospace and Industrial 's, real estate, etc.

Those that work for financial sponsors have a greater probability of exiting into PE and those that work in Life Sciences have a better shot at CorpDev/boutique strategy consulting. Life Sciences will give you a shot at VC while Compex Securities won't. I could go on but I think you get it.

If I had to generalize, I would categorize the likely exists as follows, in order to descending likelihood:

  • Middle office valuation at an Ares/Blackstone/lesser known HF sort of place - about 40% (less likely if you work in Life sciences)
  • IB - about 25% (mostly boutique and MM but there are some BB placements. This isn't sector specific since most IBs are structured by industry vertical as well)
  • ER - about 10% (seen placements into Jefferies, Guggenheim, Susquehanna, etc)
  • CorpDev about 10% (much more likely for life sciences)
  • Actual PE/VC/HF/A&M - about 5% (almost exclusively from financial sponsors and real estate valuation groups)
  • Strategy consulting about 5% - (absolutely no MBB. I've never seen it)
  • Something else - 5% (FP&A, accounting, treasury, retail financial analyst, etc.)

I should note that this does not consider bval to bval transfers, which is obviously the most likely exit. The list only considers exits from bval into something else. The list also considers the bval industry as a whole. For example, the list cites that about 5% go into PE but this is a very common exit for those in real estate valuation groups. The thing is that those groups tend to be very lean and thus only make up a small portion of the industry.

There are some nuances here. For example, I mentioned that MBB placements are basically unheard of. That said, if you work for Deloitte bval in NYC, you'll frequently be staffed on Monitor engagement (if you're good). You'll work for Monitor partners, in the Monitor building, etc. This is obviously advantageous for those looking to exit into strategy. So while MBB is basically unheard of, exits to LEK/Parthenon aren't.

“Elections are a futures market for stolen property”
  • 10
Aug 13, 2022 - 12:08pm
keepgoing12345, what's your opinion? Comment below:

Would you be able to comment on the valuation exits from the mega funds? Currently analyst on valuations team for a specific sector at a mega fund; PE valuations focused on (core PE, growth equity, lifescience, etc.) any insight here would greatly be appreciated.


Feb 10, 2018 - 3:02pm
123..., what's your opinion? Comment below:

Totam omnis numquam perferendis eius quia tenetur corporis. Enim ea provident voluptatem maxime dicta. Quos fugit non voluptatem molestias sapiente voluptas quod. Quia velit voluptatem repellat unde dolor debitis.

Qui tempore non dolores recusandae aut. Error hic blanditiis est vel et maxime earum expedita. Aut asperiores qui dignissimos repellendus impedit est aliquam. Nisi fuga unde ex. Beatae eum est dolor accusamus totam repudiandae.

Start Discussion

Popular Content See all

Career Advancement Opportunities

September 2022 Investment Banking

  • Jefferies & Company (▲05) 99.6%
  • Lincoln International (= =) 99.2%
  • Bank of America Merrill Lynch (▲04) 98.8%
  • Financial Technology Partners (+ +) 98.5%
  • Evercore (▽02) 98.1%

Overall Employee Satisfaction

September 2022 Investment Banking

  • Jefferies & Company (▲12) 99.6%
  • Greenhill (▲07) 99.2%
  • Evercore (▲01) 98.8%
  • PJT Partners (▽02) 98.4%
  • Macquarie Group Limited ABN (▲20) 98.1%

Professional Growth Opportunities

September 2022 Investment Banking

  • Jefferies & Company (▲05) 99.6%
  • Lincoln International (▲03) 99.2%
  • PwC Corporate Finance (▲12) 98.8%
  • Bank of America Merrill Lynch (▲05) 98.5%
  • Houlihan Lokey (▲05) 98.1%

Total Avg Compensation

September 2022 Investment Banking

  • Director/MD (10) $613
  • Intern/Summer Analyst (317) $408
  • Vice President (38) $392
  • Associates (208) $257
  • 2nd Year Analyst (130) $163
  • 3rd+ Year Analyst (18) $159
  • 1st Year Analyst (433) $151
  • Intern/Summer Associate (83) $150